FDA issues what consultants describe as its only supplement-side GLP-1 warning letter

On Dec. 10, 2024, the FDA sent a warning letter to a company called Veronvy over two products marketed as "Elily Veronvy" and "Elily Veronvy 40+," saying they are unapproved new drugs under the Federal Food, Drug and Cosmetic Act "because they are intended to prevent, treat or cure disease conditions and/or affect the structure or function of the body" ^[1]. More than five months later, regulatory consultants say it is still the only supplement warning letter the agency has issued over GLP-1 claims ^[1].

Asa Waldstein, principal of the regulatory firm Supplement Advisory Group, called that record "astonishing," telling SupplySide Supplement Journal that "surprisingly, there has been only one supplement-related GLP-1 warning letter" ^[1]. According to Waldstein, the company claimed its products were better than Ozempic, FDA-approved and clinically proven, and "made extreme weight-loss claims and used extreme before-and-after pictures" ^[1]. He described those as "high-risk examples of marketing statements that can trigger not only FDA scrutiny, but also FTC and plaintiff attorney lawsuit attention" ^[1]. Veronvy did not respond to a request for comment from the publication ^[1].

A crowded market with thin enforcement

The backdrop is a fast-growing consumer market. One study published in the Annals of Internal Medicine, drawing on 45 million de-identified medical records, found roughly 21,000 U.S. patients were using GLP-1 drugs for overweight or obesity in 2019, compared with 174,000 in 2023 — a 700% increase in prescriptions over four years ^[1]. J.P. Morgan Research analysts have estimated the GLP-1 drug market will exceed $100 billion by 2030 ^[1].

Larisa Pavlick, regulatory program manager of Market Integrity at Informa Markets and a former FDA investigator, said GLP-1-related supplements generally fall into two buckets: products offering nutritional support for people already taking the drugs, and products that claim to "mimic the pharmaceutical-like effect of those pharmaceutical products" ^[1]. The second group, she said, is "unfortunately … where we dive into some potential for adulteration" ^[1]. Pavlick noted weight loss is one of five supplement categories FDA watches "pretty closely" because of "a higher incidence of adulteration of those products" ^[1].

Even so, attorneys quoted in the report described regulators as largely quiet. Marc Ullman, of counsel at Rivkin Radler LLP, called the silence "an age-old problem with supplements" and said FDA "seems to be taking a fairly relaxed attitude" toward GLP-1 supplement claims "as long as they are properly framed structure-function claims" ^[1]. The FTC declined to comment and FDA did not directly respond to questions for the article ^[1].

Why it matters for patients

The practical takeaway is that a supplement on a store shelf or in a social feed may carry GLP-1 language without having been reviewed by the FDA for that use. Waldstein said "supports GLP-1" claims have not shown up in warning letters, likely because GLP-1 is a hormone the body naturally produces ^[1]. But he cautioned that "making supplement 'GLP-1 agonist' claims likely crosses the compliance line," and that risk rises when sellers add phrases like "Nature's Ozempic" or disease-adjacent terms such as "helps with nausea" ^[1].

Waldstein also explained how the agency appears to weigh risk: FDA often considers the potential health consequences if a consumer picks the supplement over a prescribed drug ^[1]. "In the case of GLP-1 drugs like Ozempic, since it is indicated for diabetes and heart disease, there may be serious health issues if a consumer foregoes medical treatment in search of a natural remedy," he said ^[1].

There is a legitimate lane, lawyers said. Katie Bond, a partner at Keller and Heckman LLP, noted FDA requires that the drugs be used along with diet and exercise, and said there is "a place to carefully, within the FDA rules," offer protein or other macronutrient support for people taking them ^[1]. Claims that a supplement increases a drug's effectiveness, she said, are "a pretty clear no-no" under an existing FDA rule ^[1]. Theodora McCormick of Baker Donelson added that brands should avoid claims that a product treats diabetes or obesity, which FDA considers a disease ^[1].

What happens next

The source does not say whether Veronvy responded to the FDA or whether further action followed, and it does not detail any broader enforcement plan ^[1]. Retailers continue to build hybrid offerings — The Vitamin Shoppe launched a telehealth service in May 2024 pairing prescription weight-loss medications with supplements and lifestyle guidance ^[1]. Whether FDA or the FTC steps up GLP-1 claim enforcement is not yet known.